Cas:325-83-7 6-(trifluoromethylsulfonyl)-1,3-benzothiazol-2-amine manufacturer & supplier

We serve Chemical Name:6-(trifluoromethylsulfonyl)-1,3-benzothiazol-2-amine CAS:325-83-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-(trifluoromethylsulfonyl)-1,3-benzothiazol-2-amine

Chemical Name:6-(trifluoromethylsulfonyl)-1,3-benzothiazol-2-amine
CAS.NO:325-83-7
Synonyms:6-Trifluormethansulfonyl-benzothiazol-2-ylamin;Trifluormethyl-<2-amino-benzthiazol-(6)-yl>-sulfon;2-AMINO-6-(TRIFLUOROMETHANESULFONYL)BENZOTHIAZOLE;6-trifluoromethanesulfonyl-benzothiazol-2-ylamine;2-AMINO-6-(TRIFLUORO-METHANESUFONYL)BENZOTHIAZOLE
Molecular Formula:C8H5F3N2O2S2
Molecular Weight:282.26300
HS Code:2934999090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:109.67000
Exact Mass:281.97400
LogP:3.83400

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 6-Trifluormethansulfonyl-benzothiazol-2-ylamin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-AMINO-6-(TRIFLUORO-METHANESUFONYL)BENZOTHIAZOLE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,-sulfon Use and application,6-trifluoromethanesulfonyl-benzothiazol-2-ylamine technical grade,usp/ep/jp grade.


Related News: Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. 1-Thien-2-yl-cyclohexan-1-carbonsaeureamid manufacturers As further tools are created to improve biocatalyst development, these can likewise be assessed for their capacity to add value to a project. 1-Tetradecen-5-one, 6-methyl- suppliers As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders. cis-2α,3α-decahydronaphthalenediol vendor & factory.